Bavencio (Avelumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The bavencio (avelumab) market size has grown rapidly in recent years. It will grow from $0.54 million in 2025 to $0.63 million in 2026 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to clinical success of immuno-oncology drugs, approval in merkel cell carcinoma, rising cancer immunotherapy investment, improved survival outcomes, regulatory support for pd-l1 inhibitors.

The bavencio (avelumab) market size is expected to see rapid growth in the next few years. It will grow to $1.17 million in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to expansion into new tumor indications, increasing global immunotherapy adoption, growth in oncology clinical trials, improved biomarker driven treatment selection, rising healthcare oncology spending. Major trends in the forecast period include growing adoption of immune checkpoint inhibitors, expansion of pd-l1 targeted therapies, rising use of immunotherapy in solid tumors, combination use with chemotherapy and targeted drugs, increased focus on rare cancer indications.

The increasing prevalence of cancer is expected to drive the growth of the Bavencio (avelumab) market going forward. Cancer comprises a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer prevalence is attributed to factors such as unhealthy lifestyle choices, including poor diet and physical inactivity, greater exposure to environmental pollutants, and improvements in diagnostic and screening technologies. Bavencio (avelumab) supports cancer treatment by acting as an immune checkpoint inhibitor that enhances the body’s natural immune response, enabling immune cells to better recognize and destroy cancer cells, while improving survival outcomes and quality of life for patients. For instance, in January 2023, according to the American Cancer Society, the number of new cancer cases in the United States reached 1,958,310 in 2023, with 609,820 cancer-related deaths reported. Therefore, the rising prevalence of cancer is driving the growth of the Bavencio (avelumab) market.

A key trend in the Bavencio (avelumab) market is the adoption of strategic partnerships to strengthen technology integration and expand market reach. Strategic partnerships involve collaborative agreements in which organizations pool resources, expertise, and capabilities to achieve shared objectives. For instance, in May 2025, Aulos Bioscience partnered with Merck KGaA in a clinical trial collaboration to evaluate a combination therapy of AU-007, an interleukin-2 (IL-2) therapeutic, with Bavencio (avelumab) and low-dose aldesleukin. The Phase 2 trial is designed to assess the potential of this combination in treating solid tumors. Bavencio’s anti-PD-L1 mechanism, together with AU-007’s immune-enhancing properties, has shown promising tumor-eradicating potential in preclinical studies.

In March 2023, Merck KGaA acquired exclusive worldwide rights to BAVENCIO (avelumab) from Pfizer Inc. for an undisclosed amount following the termination of their alliance agreement. This move aligns with Merck KGaA’s strategy to strengthen its oncology portfolio and underscores its long-term commitment to BAVENCIO as an important treatment option for cancers such as metastatic Merkel cell carcinoma and advanced renal cell carcinoma. Pfizer Inc. is a US-based pharmaceutical manufacturing company involved in the production of BAVENCIO (avelumab).

Major companies operating in the bavencio (avelumab) market are Merck & Co. Inc., Pfizer Inc.

North America was the largest region in the bavencio(avelumab) market in 2025. The regions covered in the bavencio (avelumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bavencio (avelumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the bavencio market by increasing costs for monoclonal antibody production inputs, formulation materials, and temperature-controlled logistics. These impacts are strongest in regions dependent on imported immunotherapies, including asia pacific and emerging markets. Hospital procurement and oncology clinic budgets face higher acquisition costs. On the positive side, tariffs are encouraging localized immunotherapy manufacturing investments. This strengthens regional supply security and supports long-term market expansion.

The bavencio (avelumab) market research report is one of a series of new reports that provides bavencio (avelumab) market statistics, including bavencio (avelumab) industry global market size, regional shares, competitors with a bavencio (avelumab) market share, detailed bavencio (avelumab) market segments, market trends and opportunities, and any further data you may need to thrive in the bavencio (avelumab) industry. This bavencio (avelumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bavencio (avelumab) is a medication used in the treatment of certain cancers. It contains avelumab as the active ingredient, an immunotherapy agent that works by enabling the body’s immune system to better recognize and attack cancer cells.

The main indications for Bavencio (avelumab) include Merkel cell carcinoma, non-small cell lung cancer (NSCLC), urothelial carcinoma, and gastric cancer. Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that originates in Merkel cells located in the outermost layer of the skin, known as the epidermis. The medication is administered through routes such as intravenous and subcutaneous injection and is used by end users including hospitals, clinics, and cancer research institutes.

The bavencio (avelumab) market consists of sales of monotherapy and combination therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.